Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma. METHODS: Patients with completely resected stage III melanoma were randomly assigned (with stratification according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred. Recurrence-free survival in the overall intention-to-treat population and in the subgroup of patients with cancer that was positive for the PD-1 ligand (PD-L1) were the primary end points. Safety was also evaluated. RESULTS: At a median follow-up of 15 months, pembrolizumab was associated with significantly longer recurrence-free survival than placebo in the overall intention-to-treat population (1-year rate of recurrence-free survival, 75.4% [95% confidence interval {CI}, 71.3 to 78.9] vs. 61.0% [95% CI, 56.5 to 65.1]; hazard ratio for recurrence or death, 0.57; 98.4% CI, 0.43 to 0.74; P<0.001) and in the subgroup of 853 patients with PD-L1-positive tumors (1-year rate of recurrence-free survival, 77.1% [95% CI, 72.7 to 80.9] in the pembrolizumab group and 62.6% [95% CI, 57.7 to 67.0] in the placebo group; hazard ratio, 0.54; 95% CI, 0.42 to 0.69; P<0.001). Adverse events of grades 3 to 5 that were related to the trial regimen were reported in 14.7% of the patients in the pembrolizumab group and in 3.4% of patients in the placebo group. There was one treatment-related death due to myositis in the pembrolizumab group. CONCLUSIONS: As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594 ; EudraCT number, 2014-004944-37 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [189]
Experimental — accuracy not yet measuredIn the citing paper
“Thyroid events occur in approximately 10% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 15-20% of those treated with combination PD-1/CTLA-4 blockade (as opposed to only 5% of those treated with ipilimumab monotherapy).9,38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“Any type of irAE occurs in 80-90% of patients, with higher grade events (as categorized by the Common Terminology Criteria for Adverse Events) occurring in 15-20% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 60% of patients treated with combination of ipilimumab and nivolumab.9”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“The combination of ipilimumab and nivolumab has demonstrated enhanced response rates in melanoma, lung cancer, renal cell carcinoma, and mismatch repair deficient colon cancer compared with single agent therapy, although at a cost of increased toxicities (see next section).9–11”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602 · cited 2×
“AJCC denotes American Joint Committee on Cancer 2009 classification, 7th edition.(14) 0.”
BackgroundSelf-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Self-citationAdjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
Self-citation
Cited by
Items 301–400 of 1,000
Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study
Salzmann, M., Tosev, G., Heck, M., Schadendorf, D., Maatouk, I., Enk, A., Hartmann, M., & Hassel, J. C. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.031 · Cited by 58
Self-citationLian, B., Li, Z., Wu, N., Li, M., Chen, X., Zheng, H. Y., Gao, M., Wang, D., Sheng, X., Tian, H., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.793 · Cited by 55
Self-citationThe 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis—From Conception to Treatment
Weichselbaum, R. R. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00847 · Cited by 55
Malissen, N., Macagno, N., Granjeaud, S., Granier, C., Moutardier, V., Gaudy‐Marqueste, C., Habel, N., Mandavit, M., Guillot, B., Pasero, C., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1665976 · Cited by 59
“Cohort 116 65 (56) 51 (44) Men 65 31 (48) 34 (52) Women 51 34 (67) 17 (33) Median age at initial diagnostic [range] 56 [19-89] 54 [25-86]”
Self-citationVulvar malignancies: an interdisciplinary perspective
Wohlmuth, C., & Wieser, I. (2019) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13995 · Cited by 74
Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy
Benítez, J. C., Remón, J., & Besse, B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3255 · Cited by 60
“However, adjuvant anti–PD-1 blockade with nivolumab (3) or pembrolizumab (4) demonstrated a clear benefit in relapse delay and toxicity profile compared with ipilimumab or placebo, respectively, leading to FDA approval of anti–PD-1 in the adjuvant setting.”
BackgroundFu, J., Li, W.-Z., McGrath, N. A., Lai, C. W., Brar, G., Xiang, Y.-Q., & Xie, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650292 · Cited by 51
Khan, K. A., Wu, F. T. H., Cruz‐Muñoz, W., & Kerbel, R. S. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.201708253 · Cited by 56
Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
Trojaniello, C., Luke, J. J., & Ascierto, P. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670726 · Cited by 58
“Similar RFS results were recently reported in phase III clinical trial KEYNOTE 054 (22) in which patients with stage III melanoma were randomized to treatment with pembrolizumab at a dosage of 200 mg Q3W or placebo.”
ResultSelf-citationHuang, M., Yang, J., Wang, T., Song, J. T., Xia, J., Wu, L., Wang, W., Wu, Q., Zhu, Z., Song, Y., et al. (2020) · Angewandte Chemie · doi:10.1002/ange.201916039 · Cited by 53
van Krimpen, A., Gerretsen, V. I. V., Mulder, E. E. A. P., van Gulijk, M., van den Bosch, T. P. P., von der Thüsen, J. H., Grünhagen, D. J., Verhoef, C. K., Mustafa, D. A. M., Aerts, J. G. J. V., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.009 · Cited by 53
Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study
Parlati, L., Vallet‐Pichard, A., Batista, R., Hernvann, A., Sogni, P., Pol, S., & Mallet, V. O. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.08.014 · Cited by 57
Burotto, M., Wilkerson, J., Stein, W. D., Bates, S. E., & Fojo, T. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.01.002 · Cited by 55
Proceedings From the Global Cardio-Oncology Summit
Lenihan, D. J., Fradley, M. G., Dent, S. F., Brezden‐Masley, C., Carver, J. R., Filho, R. K., Neilan, T. G., Blaes, A. H., Melloni, C., Herrmann, J., et al. (2019) · JACC CardioOncology · doi:10.1016/j.jaccao.2019.11.007 · Cited by 56
“The use of ICIs will expand from late stage disease to adjuvant and neoadjuvant use in patients with a longer anticipated survival (95).”
Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma
Braune, J., Keller, L., Schiller, F., Graf, E., Rafei-Shamsabadi, D. A., Wehrle, J., Follo, M., Philipp, U., Hussung, S., Pfeifer, D., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00174 · Cited by 55
The regulation of immune checkpoints by the hypoxic tumor microenvironment
Hu, M., Li, Y., Lu, Y., Wang, M., Li, Y., Wang, C., Li, Q., & Zhao, H. (2021) · PeerJ · doi:10.7717/peerj.11306 · Cited by 51
“, 2018), melanoma (Eggermont et al., 2018), and urothelial carcinoma (Farina, Lundgren & Bellmunt, 2017).”
BackgroundCurrent concepts of non-coding RNA regulation of immune checkpoints in cancer
Smolle, M. A., Prinz, F., Calin, G. A., & Pichler, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.09.007 · Cited by 52
Current understanding of epigenetics role in melanoma treatment and resistance
Fath, M. K., Azargoonjahromi, A., Soofi, A., Almasi, F., Hosseinzadeh, S., Khalili, S., Sheikhi, K., Ferdousmakan, S., Owrangi, S., Fahimi, M., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02738-0 · Cited by 55
“Melanoma has been rampant across the world [2], accounting for 5.”
BackgroundPersonalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Lucas, M. W., Versluis, J. M., Rozeman, E. A., & Blank, C. U. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00760-3 · Cited by 50
Self-citationAkkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy
Fan, S., Jiang, Z., Zhang, Z., Xing, J., Wang, D., & Tang, D. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05199-8 · Cited by 53
Dummer, R., Robert, C., Scolyer, R. A., Taube, J. M., Tetzlaff, M. T., Menzies, A. M., Hill, A., Grob, J., Portnoy, D. C., Lebbé, C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03411-x · Cited by 55
Self-citationAndreasen, S., Kiss, K., Mikkelsen, L. H., Channir, H. I., Plaschke, C. C., Melchior, L. C., Eriksen, J. G., & Wessel, I. (2019) · Apmis · doi:10.1111/apm.12901 · Cited by 50
Samimi, M. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00427-9 · Cited by 51
Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets
Basile, M. S., Mazzon, E., Fagone, P., Longo, A., Russo, A., Fallico, M., Bonfiglio, V. M. E., Nicoletti, F., Avitabile, T., & Reibaldi, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01145 · Cited by 56
“0% for the 1-year rate of recurrence-free survival, respectively) (126).”
BackgroundJapanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019
Nakamura, Y., Asai, J., Igaki, H., Inozume, T., Namikawa, K., Hayashi, A., Fukushima, S., Fujimura, T., Ito, T., Imafuku, K., et al. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.15151 · Cited by 52
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 53
Drobni, Z. D., Michielin, O. A., Quinaglia, T., Zlotoff, D. A., Zubiri, L., Gilman, H. K., Sama, S., Merkely, B. P., Müller, V., Sullivan, R. J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.024 · Cited by 51
Sharma, A., Alexander, G., Chu, J. H., Markopoulos, A., Maloul, G., Ayub, M. T., Fidler, M. J., & Okwuosa, T. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032620 · Cited by 52
Ascierto, P. A., Lewis, K. D., Giacomo, A. M. D., Демидов, Л. В., Mandalà, M., Bondarenko, I., Herbert, C., Mackiewicz, A. A., Rutkowski, P. L., Guminski, A. D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.002 · Cited by 51
Self-citationThe dark side of immunotherapy
Okwundu, N., Grossman, D., Hu‐Lieskovan, S., Grossmann, K. F., & Swami, U. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4750 · Cited by 52
Du, Y., Peng, Q., Cheng, D., Pan, T. S., Sun, W., Wang, H., Ma, X., He, R.-R., Zhang, H., Cui, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27936-8 · Cited by 56
Bateni, S. B., Nguyen, P., Eskander, A. E., Seung, S. J., Mittmann, N., Jalink, M., Gupta, A., Chan, K., Hong, N. J. L., & Hanna, T. P. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.3179 · Cited by 49
“9) visits or a median (IQR) of 10 (5-18) visits for injection and/or oral systemic therapy.”
BackgroundPeach, A. H. S., R. Board, Cook, M. G., Corrie, P. G., Ellis, S., Geh, J. L. C., King, P., Laitung, G., Larkin, J., Marsden, J., et al. (2019) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2019.06.020 · Cited by 48
Self-citationUse of Circulating Tumor DNA for Cancer Immunotherapy
Snyder, A., Morrissey, M., & Hellmann, M. D. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2688 · Cited by 48
“demonstrating the proof of principle that immunotherapy can prevent or delay relapse for some patients (43, 44).”
BackgroundEggermont, A. M. M., Bellomo, D., Arias‐Mejias, S. M., Quattrocchi, E., Damodaran, S. S., Bridges, A. G., Lehman, J. S., Hieken, T. J., Jakub, J. W., Murphree, D. H., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.08.029 · Cited by 52
Self-citationFear, V. S., Forbes, C. A., Neeve, S. A., Fisher, S. A., Chee, J., Waithman, J. C., Ma, S. K., Lake, R., Nowak, A. K., Creaney, J., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02934-3 · Cited by 56
Blankenstein, S. A., Rohaan, M. W., Klop, W. M. C., van der Hiel, B., van de Wiel, B. A., Lahaye, M. J., Adriaansz, S., Sikorska, K., van Tinteren, H., Sari, A., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000004893 · Cited by 49
Self-citationFrailty and checkpoint inhibitor toxicity in older patients with melanoma
Bruijnen, C. P., Koldenhof, J. J., Verheijden, R. J., van den Bos, F., Emmelot‐Vonk, M. H., Witteveen, P. O., & Suijkerbuijk, K. P. M. (2022) · Cancer · doi:10.1002/cncr.34230 · Cited by 52
Huang, L., Zhu, H., & Shi, Y. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01734-x · Cited by 52
van Akkooi, A. C. J., Hieken, T. J., Burton, E. M., Ariyan, C. E., Ascierto, P. A., Asero, S. V. M. A., Blank, C. U., Block, M. S., Boland, G. M., Caracò, C., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11236-y · Cited by 50
“Some studies are attempting such surgical de-escalation, but until there is robust evidence of the safety of this novel approach, we recommend formal TLND according to the definitions used by, for example, MSLT and EORTC.27,30,64 However, it is not clear at this time whether the decrease in tumor volume at the time of…”
MethodSelf-citationRobert, C., Gastman, B., Gogas, H. J., Rutkowski, P., Long, G. V., Chaney, M. F., Joshi, H., Lin, Y., SNYDER, W. J., & Chesney, J. A. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114120 · Cited by 53
Self-citationMetastatic Melanoma: Recent Therapeutic Progress and Future Perspectives
Malissen, N., & Grob, J. (2018) · Drugs · doi:10.1007/s40265-018-0945-z · Cited by 51
Self-citationOnesti, C. E., Frères, P., & Jérusalem, G. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.47 · Cited by 46
“In melanoma several phase III clinical trials evaluated ipilimumab, nivolumab and pembrolizumab in completely resected high risk patients, showing a relapse free survival (RFS) benefit (12,13).”
BackgroundIs the Neutrophil-to-Lymphocyte Ratio a Useful Prognostic Indicator in Melanoma Patients?
Cohen, J. T., Miner, T. J., & Vezeridis, M. P. (2020) · Melanoma Management · doi:10.2217/mmt-2020-0006 · Cited by 52
Vreeland, T. J., Clifton, G. T., Hale, D. F., Chick, R. C., Hickerson, A. T., Cindass, J. L., Adams, A. M., Bohan, P. M. K., Andtbacka, R. H. I., Berger, A. C., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09709-1 · Cited by 46
Kang, Y., & Cai, Y. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5362 · Cited by 48
Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
Wu, L., Tsang, V., Sasson, S. C., Menzies, A. M., Carlino, M. S., Brown, D. A., Clifton-Bligh, R. J., & Gunton, J. E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.764138 · Cited by 48
“In addition to metastatic malignancies, adjuvant ICI therapy with anti-PD1 has also been demonstrated to reduce risk of relapse in resected stage III or IV melanoma and resected renal cell carcinoma (11, 12).”
BackgroundSelf-citationChen, L., Jiang, X., Li, Y., Zhang, Q., Li, Q., Zhang, X., Zhang, M., Yu, Q., & Gao, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108962 · Cited by 50
Verver, D., van der Veldt, A., van Akkooi, A. C. J., Verhoef, C. K., Grünhagen, D. J., & Louwman, W. (2019) · International Journal of Cancer · doi:10.1002/ijc.32229 · Cited by 45
Current and emerging systemic therapies for cutaneous metastatic melanoma
Mason, R., Au, L., Garces, A. I., & Larkin, J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1601700 · Cited by 46
Self-citationHaydu, L. E., Lo, S., McQuade, J. L., Amaria, R. N., Wargo, J. A., Ross, M. I., Cormier, J. N., Lucci, A., Lee, J. E., Ferguson, S. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01508 · Cited by 45
“Age, years Median (range) 56 (16-95) 57 (17-95) 55 (16-89) .”
Self-citationPrognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma
Hoffmann, F., Zarbl, R., Niebel, D., Sirokay, J. D., Fröhlich, A., Posch, C., Holderried, T. A. W., Brossart, P., Saavedra, G., Kuster, P., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00883-9 · Cited by 46
“Background Immune checkpoint inhibitors of the programmed cell death (PD-1) pathway are able to induce dramatic and durable regression of metastatic melanoma, consequently leading to their regulatory approval in metastatic melanoma and also recently in the adjuvant setting [1, 2].”
BackgroundTLRs as a Promise Target Along With Immune Checkpoint Against Gastric Cancer
Cui, L., Wang, X., & Zhang, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.611444 · Cited by 48
“Blocking the PD-1 pathway inhibits the negative immune regulation of the PD-1 pathway on T cells, then the anti-tumor response is stimulated (Ribas et al., 2015; Nghiem et al., 2016; Bellmunt et al., 2017; Eggermont et al., 2018; Fuchs et al., 2018; Gandhi et al., 2018; Zhu et al., 2018; Chung et al., 2019).”
BackgroundImmune checkpoint-targeted antibodies: a room for dose and schedule optimization?
Maritaz, C., Broutin, S., Chaput, N., Marabelle, A., & Paci, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01182-3 · Cited by 52
Moncrieff, M. D., Lo, S., Scolyer, R. A., Heaton, M. J., Nobes, J. P., Snelling, A. P., Carr, M. J., Nessim, C., Wade, R. G., Peach, A. H. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02488 · Cited by 48
“Recently, several prospective randomized controlled trials have shown clinical benefit of adjuvant systemic therapy, in terms of recurrence-free survival, for patients with AJCC stage III metastatic melanoma.(2,4,5) As a result, most modern clinical guidelines recommend it for high-risk, resected stage III disease.”
BackgroundMüller‐Jensen, L., Zierold, S., Versluis, J. M., Boehmerle, W., Huehnchen, P., Endres, M., Mohr, R. U., Compter, A., Blank, C. U., Hagenacker, T., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.08.009 · Cited by 48
Self-citationExpert opinion on thyroid complications in immunotherapy
Illouz, F., Drui, D., Caron, P. J., & Cao, C. D. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.007 · Cited by 47
Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
Sahni, S., Valecha, G. K., & Sahni, A. (2018) · Cureus · doi:10.7759/cureus.3700 · Cited by 49
Huang, Q., Zheng, Y., Gao, Z., Yuan, L., Sun, Y., & Chen, H. (2020) · Journal of Cancer · doi:10.7150/jca.49325 · Cited by 48
Novel adjuvant options for cutaneous melanoma
Dimitriou, F., Long, G. V., & Menzies, A. M. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.198 · Cited by 52
Self-citationSilk, A. W., & Margolin, K. A. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.004 · Cited by 46
Curkovic, N. B., Bai, K., Ye, F., & Johnson, D. B. (2024) · Cancers · doi:10.3390/cancers16020340 · Cited by 50
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy
Rizk, E. M., Gartrell, R. D., Barker, L. W., Esancy, C. L., Finkel, G. G., Bordbar, D. D., & Saenger, Y. M. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.005 · Cited by 47
Real-world data on PD-1 inhibitor therapy in metastatic melanoma
Arheden, A., Skalenius, J., Bjursten, S., Stierner, U. K., Ny, L., Levin, M., & Jespersen, H. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1620966 · Cited by 43
“7%) in our cohort developed biopsy-verified sarcoid reactions, an immune-related AE not reported in the pivotal phase III trials, but found at a similar frequency in a more recent adjuvant trial with pembrolizumab [15].”
ResultFuture of immune checkpoint inhibitors: focus on tumor immune microenvironment
Jia, Y., Liu, L., & Shan, B. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3735 · Cited by 49
“Furthermore, Pembrolizumab can be applied as adjuvant therapy for high-risk stage III melanoma with significantly longer recurrence-free survival than placebo (103).”
BackgroundNeoadjuvant immunotherapy for melanoma
Lee, A. Y., & Brady, M. S. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26229 · Cited by 43
Ziogas, D. C., Gkoufa, A., Cholongitas, E., Diamantopoulos, P., Anastasopoulou, A., Ascierto, P. A., & Gogas, H. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001322 · Cited by 43
Self-citationNahar, K. J., Rawson, R. V., Ahmed, T., Tattersall, S., Sandanayake, N. S., Kiely, C. J., Lo, S., Carlino, M. S., Palendira, U., Scolyer, R. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001488 · Cited by 43
Self-citationLian, B., Si, L., H., Z., Sheng, X., Kong, Y., Wang, X., Tian, H., Li, K., Mao, L., Bai, X. L., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.002 · Cited by 43
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
Garbe, C., Dummer, R., Amaral, T. M. S., Amaria, R. N., Ascierto, P. A., Burton, E. M., Dréno, B., Eggermont, A. M. M., Hauschild, A., Höeller, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02336-1 · Cited by 45
Self-citationAdjuvant Pembrolizumab in Resected Stage III Melanoma
Eggermont, A. M. M., Robert, C., & Suciu, S. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1807505 · Cited by 43
Self-citationBhatlapenumarthi, V., Patwari, A., & Harb, A. J. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03610-w · Cited by 45
“The most common irAEs associated with ICIs reported in clinical trials are GI (colitis, diarrhea), dermatological (rash, pruritis), and endocrine (hypo and hyperthyroidism) (Robert et al. 2015; Borghaei et al. 2015; Herbst et al. 2016; Eggermont et al. 2018; Rittmeyer et al. 2017; Garassino et al. 2018).”
BackgroundIt is finally time for adjuvant therapy in melanoma
Napolitano, S., Brancaccio, G., Argenziano, G., Martinelli, E., Morgillo, F., Ciardiello, F., & Troiani, T. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.06.003 · Cited by 45
Updates in adjuvant systemic therapy for melanoma
Kwak, M., Farrow, N. E., Salama, A. K. S., Mosca, P. J., Hanks, B. A., Slingluff, C. L., & Beasley, G. M. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25298 · Cited by 46
“Pembrolizumab was also effective in patients with PD‐L1– negative tumors and in those with undetermined tumor PD‐L1 expression.(5) Similar to Checkmate‐238, this trial’s secondary endpoint of OS is pending.”
BackgroundMethodResultInfluentialPoly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth
Aurisicchio, L., Salvatori, E., Lione, L., Bandini, S., Pallocca, M., Maggio, R., Fanciulli, M., Nicola, F. D., Goeman, F., Ciliberto, G., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1084-4 · Cited by 45
“The efficacy of adjuvant immunotherapy with ICI was recently demonstrated in the clinic for anti PD-1 pembrolizumab [25] and it was previously shown to be effective for the anti CTLA-4 ipilimumab [26].”
BackgroundWu, C., Yang, C., Peng, M., Huang, P., Chang, C., Yeh, K., Chen, C., Wang, C., Hsu, C., Chen, I., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07508-7 · Cited by 43
Cutaneous melanoma in adolescents and young adults
Indini, A., Brecht, I. B., Vecchio, M. D., Sultan, I. Y., Signoroni, S., & Ferrari, A. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27292 · Cited by 44
Gong, J., Hendifar, A. E., Tuli, R., Chuang, J., Cho, M. T., Chung, V. M., Li, D., & Salgia, R. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0210-9 · Cited by 42
Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers
Hyams, D. M., Cook, R. W., & Buzaid, A. C. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25319 · Cited by 45
Oliva, I. C. G., & Alqusairi, R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_2 · Cited by 41
Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives
Testori, A., Ribero, S., Indini, A., & Mandalà, M. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00456-4 · Cited by 45
New paradigm for stage III melanoma: from surgery to adjuvant treatment
Ascierto, P. A., Borgognoni, L., Botti, G., Guida, M., Marchetti, P., D, S. M. M., Muto, P., Palmieri, G., Patuzzo, R., Quaglino, P., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2012-2 · Cited by 42
Self-citationHuman Plasmacytoid Dendritic Cells and Cutaneous Melanoma
Monti, M., Consoli, F., Vescovi, R., Bugatti, M., & Vermi, W. (2020) · Cells · doi:10.3390/cells9020417 · Cited by 43
Design and Encapsulation of Immunomodulators onto Gold Nanoparticles in Cancer Immunotherapy
Chauhan, A., Khan, T. A., & Omri, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158037 · Cited by 43
“After complete resection, it was observed that patients who received pembrolizumab every three weeks for up to one year had significantly longer recurrence-free survival than those who received placebo (NCT02362594) [42].”
BackgroundAmaral, T. M. S., Sinnberg, T. W., Chatziioannou, E., Niessner, H., Leiter, U., Keim, U., Forschner, A., Dwarkasing, J. T., Tjien-Fooh, F. J., Wever, R., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.021 · Cited by 41
Self-citationFertility preservation and management of pregnancy in melanoma patients requiring systemic therapy
Hassel, J. C., Livingstone, E., Allam, J., Behre, H. M., Bojunga, J., Klein, H. H., Landsberg, J., Nawroth, F., Schüring, A. N., Susok, L., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100248 · Cited by 45
Vardarli, I., Tan, S., Brandenburg, T., Weidemann, F., Görges, R., Herrmann, K., & Führer, D. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad670 · Cited by 44
Nijhuis, A. A. G., Dieng, M., Khanna, N., Lord, S. J., Dalton, J., Menzies, A. M., Turner, R. M., Allen, J., Saw, R. P. M., Nieweg, O. E., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07311-0 · Cited by 40
Brar, G., & Shah, M. A. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819869767 · Cited by 41
Adjuvant Therapy for Melanoma: Past, Current, and Future Developments
Testori, A., Chiellino, S., & van Akkooi, A. C. J. (2020) · Cancers · doi:10.3390/cancers12071994 · Cited by 40
“Another study with an adjuvant anti-PD-1 agent was the EORTC 1325/Keynote 054 study, which randomized stage IIIA (>1 mm), IIIB, and IIIC to either a year of 3-weekly fixed dose pembrolizumab 200 mg or placebo [47].”
MethodUltraviolet radiation drives mutations in a subset of mucosal melanomas
Mundra, P. A., Dhomen, N. S., Rodrigues, M. J., Mikkelsen, L. H., Cassoux, N., Brooks, K. M., Valpione, S., Reis-Filho, J. S., Heegaard, S., Stern, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20432-5 · Cited by 43
Tonella, L., Pala, V., Ponti, R., Rubatto, M., Gallo, G., Mastorino, L., Avallone, G., Merli, M., Agostini, A., Fava, P., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094561 · Cited by 41
“Despite the good results obtained in terms of PFS and OS [11,14,15], there is a high need for reproducible, sensitive, and “easy-to-use” biomarkers, to guide the clinical decision-making process.”
BackgroundHan, J. W., & Yoon, S. K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091387 · Cited by 42
“The use of adjuvant pembrolizumab in stage III resected patients [37] and nivolumab in stage III and IV resected patients [38] reduced the risk of relapse by 40–50% and was approved by the FDA.”
BackgroundThymic health and immunotherapy outcomes in patients with cancer
Bernatz, S., Prudente, V., Pai, S., Kjær, A., Federico, A. D., Rowan, A., Veeriah, S., Dyrskjøt, L., Nürnberg, L., Alessi, J. V., et al. (2026) · Nature · doi:10.1038/s41586-026-10243-x · Cited by 47
“Although immunotherapy is increasingly being applied in oncology, only a subset of patients respond 9–11 .”
Immune Checkpoint Blockade across the Cancer Care Continuum
Helmink, B. A., Gaudreau, P.-O., & Wargo, J. A. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.003 · Cited by 41
Principles of Immunotherapy in Melanoma
Onitilo, A. A., & Wittig, J. A. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.009 · Cited by 42
Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect
Bai, X. L., & Flaherty, K. T. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19394 · Cited by 42
Efficacy of immune checkpoint inhibitors in different types of melanoma
Rossi, E., Schinzari, G., Maiorano, B. A., Indellicati, G., Stefani, A. D., Pagliara, M. M., Fragomeni, S. M., Luca, E. V. D., Sammarco, M. G., Garganese, G., et al. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1771986 · Cited by 42
“Only one death was reported in the pembrolizumab group.(53) Immune checkpoint inhibitors and anti-BRAF/MEK agents”
BackgroundZhou, J., Liang, B., Liu, J., Jin, S., He, S., Frey, B., Gu, N., Fietkau, R., Hecht, M., Ma, H., et al. (2021) · Cells · doi:10.3390/cells10050977 · Cited by 50
“Therapies based on blockade of PD-1 in human melanoma achieved a success [6,7]; nivolumab (an anti-PD-1 monoclonal antibody) [8], and pembrolizumab (another anti-PD-1 monoclonal antibody) [9] monotherapy improve relapse/recurrence-free survival of stage III melanoma patients.”
BackgroundLong-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
Tong, J., Kartolo, A., Yeung, C., Hopman, W. M., & Baetz, T. D. (2022) · Current Oncology · doi:10.3390/curroncol29100629 · Cited by 43
Metadata
- Authors
- Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., van den Eertwegh, A. J. M., Grob, J.-J., Gutzmer, R., Jamal, R., Lorigan, P., Ibrahim, N., Marreaud, S., van Akkooi, A. C. J., Suciu, S., & Robert, C.
- Affiliations
- Aix-Marseille Université (FR)
- From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique–Hôpitaux de Marseille, Marseille (J.-J.G.) — all in France; Netherlands Cancer Institute–Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical...
- The University of Sydney (AU)
- The University of Queensland (AU)
- Edith Cowan University (AU)
- Washington University in St. Louis (US)
- University of Siena (IT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Eggermont, Alexander M.M.
- Blank, Christian U.
- Long, Georgina V.
- Atkinson, Victoria
- Dalle, Stéphane
- Haydon, Andrew
- Khattak, Adnan
- Carlino, Matteo S.
- Sandhu, Shahneen
- Larkin, James
- Puig, Susana
- Ascierto, Paolo A.
- Rutkowski, Piotr
- Schadendorf, Dirk
- Koornstra, Rutger
- Hernandez-Aya, Leonel
- Maio, Michele
- Grob, Jean-Jacques
- Gutzmer, Ralf
- Jamal, Rahima
- Lorigan, Paul
- Ibrahim, Nageatte
- Marreaud, Sandrine
- Suciu, Stefan
- Robert, Caroline
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-10
- Volume
- 378
- Issue
- 19
- Pages
- 1789-1801
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2797309423
- Cited by
- 1,906
- References
- 31
- Citations by year
- 2026: 131 · 2025: 171 · 2024: 207 · 2023: 204 · 2022: 236 · 2021: 308 · 2020: 307 · 2019: 250 · 2018: 87
- FWCI
- 88.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Australasian Journal of Paramedicine (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, public-domain)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, adjuvant therapy, stage III melanoma, PD-1 inhibitors, PD-L1 expression, recurrence-free survival, resected melanoma, immune checkpoint inhibitors, adverse events, myositis, non-relapse mortality, overall survival, progression-free survival, high-risk melanoma, tumor recurrence prevention, safety and tolerability
- MeSH terms
- Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Survival Rate, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.